Global CAR-T Cell Therapy Market to Grow with Rising Incidence of B-Cell Cancers


The demand within the global CAR-T cell therapy market is expected to rise at a stellar pace in the years to follow. The domain of oncology has gained momentum in recent times, mainly due to an increase in the incidence of chronic cancers. Several healthcare practitioners have emphasized on the need to develop fresh treatment lines for treating chronic tumors. In response to this need, medical research centers have invested their time and resources in conceptualizing fresh models for cancer treatment. The development of CAR-T cell therapy is a part of the initiatives taken by the medical research sector to treat cancers. Therefore, investments in the CAR-T cell therapy market are expected to multiply in the years to follow.

In this blog review, several factors and trends compounding the growth of the global CAR-T cell therapy market have been enunciated. The review evaluates the impact of advancements in oncology on the growth of the global CAR-T cell therapy market. Over the next decade, approvals and certifications from key healthcare authorities would play a defining role in market expansion.

Development of Fresh Lines to Treat Cancers

The basis of cancer treatments is to attack the tumor cells in the patient’s body. The development of antigens that can attack these tumors is an important consideration for the medical fraternity. CAR-T cell therapy involves the use of chimeric antigen receptors to attack the tumor. The success of this therapy in treating people suffering from severe-stage cancers has given an impetus to market growth. Furthermore, advancements in immunization therapies and antibody development has also gained momentum in these times. It is important for the healthcare industry to ensure seamless adoption of new technologies for cancer treatment.

B-cell Cancer Therapies Gain Popularity

Research related to B-cell cancers has gained priority in recent years, and this is an important consideration from the perspective of market growth. Clinical studies have also focused on studying B-cell cancers, shifting focus from other types of cancers. Therefore, the relevance of CAR-T cell therapy for treating B-type cancers has created a plethora of opportunities for market expansion. Over the course of the next decade, a number of technologies and treatment lines pertaining to CAT-T therapies could make their way into the market. Approvals by the Food and Drug Administration (FDA) have played a crucial role in driving demand within the global market. These approvals are based on safety measures related to the use of cancer therapies. Around 364 clinical trials were running acrossvarious research entities as of March 2019. Approvals of these trials would play a defining role in driving demand within the market.

To Get an Exhaustive Overview about the Competition in CAR-T Cell Therapy Market, Request for a Report Brochure at

Evaluating Restraints and Analyzing Healthcare Opportunities

There is no contention about the relevance of CAR-T cell therapies for cancer treatment. They have caused a paradigm shift in the way medical practitioners view cancer treatments. However, the breakthrough in cancer treatment caused by the development of these therapies comes with certain limitations. The survival rate of patients treated using these therapies is much lower than expected. This poses a problem for healthcare professionals and oncologists aiming to leverage new lines of treatment. In addition to this, several side effects of CAR-T cell therapy have come to the fore in recent times. These side effects have compelled oncologist to show restraint in the use of CAR-T cell therapies. However, the absence of alternative lines of treatment for attacking B-type cancer cells shall continue to drive demand within the global market.

Two of the leading vendors operating in the global CAR-T cell therapy market are Gilead Sciences, Inc. and Novartis AG. These companies are making visible efforts to commercialize their CAR-T therapies.

Leave a Reply